Medigus announced its financial results for the second quarter of 2017.
Medigus (NASDAQ:MDGS) announced its financial results for the second quarter of 2017.
As quoted in the press release:
“This quarter, we continued our efforts of commercial expansion of MUSE™ into Europe and beyond — an indication that we are on track to deliver on our long-term growth objectives,” said Chris Rowland, CEO of Medigus. “Coupled with clinical trials performances in China and our continued reductions in expenses, we believe we are rapidly approaching an important inflection in our business where we will continue to build on our vision of delivering an effective and minimally-invasive treatment option for GERD patients.”